| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhan,Qing-Liu | Chairman | 1.01% | |
| Huang,Zheng-Gu | Director | 0.51% | |
| Lin,Guo-Zhong | Director | 1.32% | |
| Xu,Xue-Fang | Director | 1.81% | HONG KONG YION CAPITAL GROUP LIMITED |
| Xiao,Zhen-Rong | Director | 6.45% | NATIONAL DEVELOPMENT FUND MANAGEMENT COMMITTEE, EXECUTIVE YUAN |
| JEFFREY READ WILLIAMS | Independent Director | 0.00% | |
| Zhang,Jin-De | Director | 0.03% | |
| Xie,Ming-Juan | Independent Director | 0.00% | |
| Liu,Jing-Cun | Independent Director | 0.08% | |
| Li,Shen-Yi | Director | 0.24% | |
| Tian,Jian-He | Independent Director | 0.00% |
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 3,257,306 | 9,734,814 | 5,105,615 |
| Operating cost | 362,516 | 1,177,225 | 610,544 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 2,894,790 | 8,557,589 | 4,495,071 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 2,894,790 | 8,557,589 | 4,495,071 |
| Operating expenses | 1,789,509 | 6,821,512 | 6,408,465 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 1,105,281 | 1,736,077 | -1,913,394 |
| Non-operating income and expenses | 355,200 | 1,258,575 | 926,460 |
| Net profit (loss) before tax | 1,460,481 | 2,994,652 | -986,934 |
| Income tax expense (benefits) | 196,924 | 29,149 | -363,099 |
| Net profit (loss) of ongoing business for the current period | 1,263,557 | 2,965,503 | -623,835 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 1,263,557 | 2,965,503 | -623,835 |
| Other comprehensive profit (loss), net | 348,527 | 297,086 | 119,374 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 1,612,084 | 3,262,589 | -504,461 |
| Net profit (loss) attributable to owners of parent company | 1,263,557 | 2,965,503 | -623,835 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | 1,612,084 | 3,262,589 | -504,461 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 3 | 8 | -1 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 1,061,389 | 2,546,905 | -705,562 |
| Net cash inflows (outflows) from investing activities | -283,912 | -1,334,900 | -486,653 |
| Net cash inflow (outflow) from financing activities | -46,902 | -185,213 | 10,454,426 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 252,656 | 358,270 | 100,160 |
| Increase (decrease) in cash and cash equivalents in the current period | 983,231 | 1,385,062 | 9,362,371 |
| Beginning balance of cash and cash equivalents | 21,051,091 | 19,666,029 | 10,303,658 |
| Ending balance of cash and cash equivalents | 22,034,322 | 21,051,091 | 19,666,029 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 26,899,010 | 25,417,485 | 22,896,158 |
| Non-current asset | 6,124,508 | 5,644,148 | 4,373,159 |
| Total asset | 33,023,518 | 31,061,633 | 27,269,317 |
| Current liability | 2,966,831 | 2,557,232 | 2,152,093 |
| Non-current liability | 933,627 | 1,035,557 | 1,169,074 |
| Total liability | 3,900,458 | 3,592,789 | 3,321,167 |
| share capital | 3,419,471 | 3,417,914 | 3,402,639 |
| Equity - secruity token | - | - | - |
| capital reserve | 23,567,568 | 23,546,569 | 24,092,179 |
| retained earning | 4,237,139 | 2,973,582 | -631,187 |
| Other equity | 703,990 | 335,887 | -110,373 |
| Treasury stock | -2,805,108 | -2,805,108 | -2,805,108 |
| Total equity attributable to owners of parent company | 29,123,060 | 27,468,844 | 23,948,150 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 29,123,060 | 27,468,844 | 23,948,150 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 8,905,000 | 8,905,000 | 8,905,000 |
| Net asset value per share | 87 | 82 | 72 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 藥品 | 國立成功大學醫學院附設醫院 | 112/12/27 | 5940000.0 | 是 |
| NTUH-P11303藥品招標案 | 國立臺灣大學醫學院附設醫院 | 112/10/26 | 是 | |
| 治療成人真性紅血球增多症藥品招標案 | 臺北市立聯合醫院 | 112/06/17 | 21300000.0 | 是 |
| 臨購血腫藥品採購案 | 衛生福利部臺中醫院 | 111/12/16 | 7488000.0 | 是 |
| 藥品一批單價合約 | 國立臺灣大學醫學院附設醫院 | 111/09/01 | 是 | |
| 藥品 | 國立成功大學醫學院附設醫院 | 110/12/30 | 否 | |
| 藥品79項(開口契約) | 高雄榮民總醫院 | 110/11/09 | 是 | |
| 藥品52項(開口契約)(本次招標16項) | 高雄榮民總醫院 | 110/03/17 | 是 | |
| 藥品 | 國立成功大學醫學院附設醫院 | 109/11/10 | 4656000.0 | 是 |
Others
2019
Fulfill contract
2019, 2020
Determine legal expenses
2009
Restitution of unjust enrichment
2019
Revocation of resolutions of shareholders' meeting
2009, 2010
Confirmation of the existence of employment relationship, etc
2007, 2008
Others
2014, 2015, 2017
Return deposit
2017
Fulfill contract
2021, 2022
Return seal stamp
2009, 2010
Motion of objection
2017
Invalidating Judgment
2006
Determine legal expenses
2017
Motion of objection (return of deposit)
2017
Revocation of resolutions of shareholders' meeting
2011, 2012
Confirmation of the existence of employment relationship, etc
2008, 2009
